Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Bioequivalence Study With Pharmacokinetic Endpoints Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

NCT05085587 is registered in ClinicalTrials.gov with Respirent Pharmaceuticals Co Ltd. as lead sponsor.

NCT NCT05085587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05085587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Bioequivalence Study With Pharmacokinetic Endpoints Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Lead sponsor
Respirent Pharmaceuticals Co Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
October 1, 2021
Completion date
December 30, 2021
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, bioequivalence